Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 2/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2967803 | 1.00 | ADRA2A (0.47) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL3025348 | 1.00 | ADRA2A (0.47) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL18219540 | 0.83 | TAAR1 (0.39) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL4369978 | 0.83 | TAAR1 (0.37) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL13211529 | 0.81 | DPP4 (0.54) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL3022672 | 0.81 | DPP4 (0.54) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL12700905 | 0.81 | DPP4 (0.54) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL667241 | 0.81 | DPP4 (0.54) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL13211530 | 0.81 | DPP4 (0.54) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL4379944 | 0.79 | TAAR1 (0.36) | ADRA2AADRA2CLMNAHIF1AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4543841-A2 | CATALYTIC CARBOXYCARBONYLATION OF ALKENES TO FORM ANHYDRIDES | The University of North Carolina at Chapel Hill (US) | 2025-04-30 | — | — | EP | disclosed |
| EP-3995492-B1 | A TWO-STEP PROCESS FOR PREPARING 3-SUBSTITUTED PHENYLALKYLAMINES | SpecGx LLC (US) | 2024-05-29 | — | — | EP | disclosed |
| WO-2023250180-A2 | CATALYTIC CARBOXYCARBONYLATION OF ALKENES TO FORM ANHYDRIDES | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2023-12-28 | — | — | WO | disclosed |
| EP-3166923-B1 | PROCESS FOR PREPARING SUBSTITUTED PHENYLALKANES | SpecGx LLC (US) | 2023-03-15 | — | — | EP | disclosed |
| EP-3995492-A1 | A TWO-STEP PROCESS FOR PREPARING 3-SUBSTITUTED PHENYLALKYLAMINES | SpecGx LLC (US) | 2022-05-11 | — | — | EP | disclosed |
| EP-3319941-B1 | A TWO-STEP PROCESS FOR PREPARING 3-SUBSTITUTED PHENYLALKYLAMINES | SpecGx LLC (US) | 2021-12-29 | — | — | EP | disclosed |
| US-10385084-B2 | Iron(II) catalysts containing tridentate PNP ligands, their synthesis, and use thereof | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2019-08-20 | — | — | US | disclosed |
| EP-3319941-A1 | A TWO-STEP PROCESS FOR PREPARING 3-SUBSTITUTED PHENYLALKYLAMINES | SpecGx, LLC (US) | 2018-05-16 | — | — | EP | disclosed |
| US-9914695-B2 | Two-step process for preparing 3-substituted phenylalkylamines | MALLINCKRODT LLC (US) | 2018-03-13 | — | — | US | disclosed |
| EP-3166923-A1 | PROCESS FOR PREPARING SUBSTITUTED PHENYLALKANES | Mallinckrodt LLC (US) | 2017-05-17 | — | — | EP | disclosed |
| WO-2013120860-A1 | PROCESS FOR THE STEREOSELECTIVE PREPARATION OF A PYRAZOLE CARBOXAMIDE | SYNGENTA PARTICIPATIONS AG (CH) | 2013-08-22 | — | — | WO | disclosed |
| US-8344187-B2 | Practical method for reducing esters or lactones | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2013-01-01 | — | — | US | disclosed |
| US-8344187-B2 | Practical method for reducing esters or lactones | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2013-01-01 | — | — | US | disclosed |
| US-20110092747-A1 | Practical Method for Reducing Esters or Lactones | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2011-04-21 | — | — | US | disclosed |
| US-20110092747-A1 | Practical Method for Reducing Esters or Lactones | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2011-04-21 | — | — | US | disclosed |
| EP-2298723-A1 | PRACTICAL METHOD FOR REDUCING ESTERS OR LACTONES | Tokyo Institute of Technology (JP) | 2011-03-23 | — | — | EP | disclosed |
| US-7772445-B2 | catalyzing the reaction of ketones or aldehydes to an alcohol derivative in presence of a ruthenium-aryl-aminophosphine complex; convert acetophenone to phenylethanol or 4-tert-butylcyclohexanone to cis-4-tert-butylcyclohexanol | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2010-08-10 | — | — | US | disclosed |
| EP-2167515-A1 | METHOD FOR THE PREPARATION OF AMINOPHOSPHINE LIGANDS AND THEIR USE IN METAL CATALYSTS | Kanata Chemical Technologies Inc. (CA) | 2010-03-31 | — | — | EP | disclosed |
| US-20090023961-A1 | catalyzing the reaction of ketones or aldehydes to an alcohol derivative in presence of a ruthenium-aryl-aminophosphine complex; convert acetophenone to phenylethanol or 4-tert-butylcyclohexanone to cis-4-tert-butylcyclohexanol | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2009-01-22 | — | — | US | disclosed |
| WO-2008148202-A1 | METHOD FOR THE PREPARATION OF AMINOPHOSPHINE LIGANDS AND THEIR USE IN METAL CATALYSTS | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10385084-B2 | Iron(II) catalysts containing tridentate PNP ligands, their synthesis, and use thereof | PNP, PNPO, FECH | ADRA2A 4606/4885ADRA2C 4539/4885LMNA 4266/4885 |
| US-20090023961-A1 | catalyzing the reaction of ketones or aldehydes to an alcohol derivative in presence of a ruthenium-aryl-aminophosphine complex; convert acetophenone to phenylethanol or 4-tert-butylcyclohexanone to cis-4-tert-butylcyclohexanol | ADH5, ADH1A, ADH1C | ADRA2A 1571/4885ADRA2C 508/4885LMNA 4332/4885 |
| US-20110092747-A1 | Practical Method for Reducing Esters or Lactones | F8, CA7, HSD11B2 | ADRA2A 4602/4885ADRA2C 4647/4885LMNA 1872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.